Analysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Price Target at $40.60

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $40.60.

A number of research firms have commented on DAWN. Piper Sandler reiterated an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday. The Goldman Sachs Group reduced their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Finally, Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 3,242 shares of Day One Biopharmaceuticals stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $49,440.50. Following the completion of the sale, the general counsel now directly owns 16,585 shares of the company’s stock, valued at $252,921.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, General Counsel Adam Dubow sold 3,242 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $49,440.50. Following the completion of the sale, the general counsel now owns 16,585 shares in the company, valued at $252,921.25. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Samuel C. Blackman sold 2,258 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the transaction, the insider now owns 1,244,662 shares in the company, valued at $18,981,095.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 45,781 shares of company stock worth $722,960. 8.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Quest Partners LLC acquired a new position in Day One Biopharmaceuticals during the 4th quarter valued at about $29,000. China Universal Asset Management Co. Ltd. boosted its holdings in Day One Biopharmaceuticals by 130.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock worth $27,000 after acquiring an additional 1,262 shares during the last quarter. Metropolitan Life Insurance Co NY grew its stake in shares of Day One Biopharmaceuticals by 77.2% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 2,736 shares of the company’s stock worth $33,000 after acquiring an additional 1,192 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Day One Biopharmaceuticals in the second quarter valued at about $51,000. Finally, Quintet Private Bank Europe S.A. lifted its position in shares of Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after purchasing an additional 1,000 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Stock Up 1.7 %

DAWN opened at $15.79 on Friday. Day One Biopharmaceuticals has a 12-month low of $9.67 and a 12-month high of $17.85. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -6.63 and a beta of -1.48. The business has a 50 day moving average of $15.11 and a 200-day moving average of $13.52.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, analysts expect that Day One Biopharmaceuticals will post -2.66 earnings per share for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.